A federal health agency is blaming “slow” marijuana research progress on the drug’s restrictive Schedule I status but says it is committed to funding studies into how cannabis can help people manage pain in spite of budget cuts recently proposed by President Donald Trump.
“A growing body of literature suggests that the cannabis plant has pain-relieving properties; however, as a schedule I substance with known psychoactive effects, research on the potential pain-relieving properties of cannabis has been slow,” the National Center for Complementary and Integrative Health (NCCIH) said in a budget justification document published on Wednesday.
NCCIH supports studies into non-conventional medicines and therapies that can be used as an alternative or supplement to traditional treatments for a variety of conditions, but the president’s Fiscal Year 2020 budget would cut its funding by about $20 million, the agency said in the new overview.
“The FY 2020 President’s Budget reflects the Administration’s fiscal policy goals for the Federal Government,” it wrote. “Within that framework, NCCIH will pursue its highest research priorities through strategic investments and careful stewardship of appropriated funds.”
Cannabis research apparently meets that standard as a high research priority, though, with the agency saying it will be announcing a funding opportunity for scientists interested in exploring medical marijuana as a natural product in the treatment of pain.
“NCCIH plans to expand efforts around natural products for pain management,” the agency wrote. “Natural products have historically been a source of novel pain-relieving compounds developed into pharmaceuticals (e.g., willow bark into aspirin).”
The funding opportunity it plans to announce will “support research on the diverse components of cannabis to explore if the pain-relieving properties can be separated from the psychoactive properties and to further characterize those components that may reduce pain.” Read more